Free Trial
OTCMKTS:BVNRY

Bavarian Nordic Q3 2025 Earnings Results & Report

Bavarian Nordic logo
$11.68 -0.11 (-0.93%)
As of 09:45 AM Eastern

Bavarian Nordic reported Q3 2025 earnings on November 14, 2025. The company reported EPS of $0.72, while revenue was $281.11 million.

Earnings Announcement Details

Quarter
Q3 2025
Time
Before Market Opens

Bavarian Nordic EPS Results

Actual EPS
$0.72
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A
EPS Beat Rate
4 of last 5 quarters

Bavarian Nordic Revenue Results

Actual Revenue
$281.11 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Conference Call Resources

Bavarian Nordic Q3 2025 Earnings FAQ

Bavarian Nordic (OTCMKTS:BVNRY) reported earnings of $0.72 per share for Q3 2025. The report was announced on Friday, November 14, 2025.

Bavarian Nordic reported revenue of $281.11 million for Q3 2025.

Bavarian Nordic Earnings Headlines

Bavarian Nordic beats Q3 revenue expectations
Top Trader Reveals Stunning Black Friday Deal
Others paid $500 for the Snapback Indicator. This Black Friday, it's available for just $7. Base Camp Trading's Thomas Wood calls it one of the firm's most powerful proprietary trading indicators, and says the company has never run a deal like this before. There are no strings attached, just a steep Black Friday discount on a tool built for traders.tc pixel
See More Bavarian Nordic Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Bavarian Nordic? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Bavarian Nordic and other key companies, straight to your email.

About Bavarian Nordic

Bavarian Nordic (OTCMKTS:BVNRY) is a Danish biotechnology company that develops, manufactures and markets vaccines for infectious diseases and cancer immunotherapy. Founded in 1994, the company is based in Denmark and serves markets in Europe, North America and other regions.

Its best-known vaccine is JYNNEOS, also marketed as IMVANEX in Europe and IMVAMUNE in Canada, for protection against smallpox and mpox. Bavarian Nordic also offers vaccines for diseases including rabies, tick-borne encephalitis, typhoid fever and cholera.

The company uses its MVA-BN technology in vaccine development and supplies products to public health authorities as well as commercial markets. Its portfolio includes vaccines developed in-house and products added through acquisitions.

View Bavarian Nordic Profile